$0M
Ecosystem Market Cap1 (source 1)
$0.0M+
Research Funded2 (source 2)
0+
Projects Launched3 (source 3)
0K+
Community Members4 (source 4)
Trusted by frontier DeSci Projects
“A growing number of scientists and entrepreneurs are leveraging blockchain tools, in an attempt to improve modern science. Collectively, their work has become known as the decentralized science movement, or DeSci.”
a16z crypto
Featured Labs
An open global community collectively sourcing and nurturing solutions to advance brain health and prevent neurodegeneration with a focus on tackling Alzheimer's first.
7
Projects Funded
$947.79K
Funding Deployed
Top Project
Transfidelity for Protein Stability
Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.
An autonomous AI agent for peptide drug discovery. Researchers specify a protein target, and the agentic fleet sources candidate peptides, evaluates each against a multi-parameter screening cascade, and advances only those meeting all criteria. Candidate peptides are validated in the lab.
2
Projects Funded
$17.75K
Funding Deployed
Top Project
KISS1R: Phase 1 Wet-Lab — KP-10 Reference + ncAA Leads C1-01, C1-02
C1-01 (D-Tyr¹/Arg(Me)⁹) and C1-02 (Ac/D-Tyr¹/Thr⁵/azaGly⁷/Arg(Me)⁹) are ncAA-modified kisspeptin decapeptide agonists of KISS1R (GPR54) selected from the Generation 1 computational pipeline (PRODIGY-estimated Kd 0.64 nM and ~140 pM respectively). This Phase 1 wet-lab compares both leads against the natural-AA reference KP-10 (YNWNSFGLRF-NH2) at Adaptyv (BLI + NPFFR1/NPFFR2 selectivity counter-screens), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS on leads.
VitaDAO's mission is to extend human healthspan and lifespan through accelerated research, open collaboration, and innovative funding structures that align incentives across the longevity ecosystem.
17
Projects Funded
$4.1M
Funding Deployed
Top Project
Mutation-Specific Codon Suppression for Aging and Longevity
Artan Bio has proposed a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. The solution involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.
